TLR-MD2-fusion protein for the treatment of infectious diseases, chronic inflammatory diseases and sepsis
The recombinant TLR-MD-2 fusion protein or a fusion protein homopolymer / heteropolymer complex can be used for the prophylactic and/or therapeutic treatment of allergic reactions, infections diseases and inflammatory conditions, such as sepsis.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Self-Destructing Cancer Cells: Cutting-Edge RNA Breakthrough
Jülich scientists use novel RNA technology to selectively switch off tumours in the brain. An Adaptable Platform Technology That Destroys Glioblastoma Cancer Cells Using a special RNA molecule, a team…
Endurance Training: Transforming Lives of Heart Failure Patients
Can strength and endurance training be beneficial for patients with a certain form of heart failure? A research team from Greifswald investigated this question together with seven other research centers…
A Wake-Up Call for Mediterranean Shark Protection Against Extinction
Overfishing, illegal fishing and increasing marketing of shark meat pose significant threats to the more than 80 species of sharks and rays that inhabit the Mediterranean Sea, according to a…